SEC Info℠ | Home | Search | My Interests | Help | Sign In | Please Sign In | ||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 3/09/21 Marinus Pharmaceuticals Inc. 10-K 12/31/20 65:7.6M Toppan Merrill Bridge/FA |
Document/Exhibit Description Pages Size 1: 10-K Annual Report HTML 1.27M 2: EX-4.3 Instrument Defining the Rights of Security Holders HTML 41K 6: EX-10.22 Material Contract HTML 67K 3: EX-10.3 Material Contract HTML 78K 4: EX-10.4 Material Contract HTML 64K 5: EX-10.9 Material Contract HTML 72K 7: EX-21 Subsidiaries List HTML 17K 8: EX-23.1 Consent of Expert or Counsel HTML 21K 9: EX-23.2 Consent of Expert or Counsel HTML 18K 10: EX-31.1 Certification -- §302 - SOA'02 HTML 24K 11: EX-31.2 Certification -- §302 - SOA'02 HTML 24K 12: EX-32.1 Certification -- §906 - SOA'02 HTML 21K 19: R1 Document and Entity Information HTML 82K 20: R2 Consolidated Balance Sheets HTML 89K 21: R3 Consolidated Balance Sheets (Parenthetical) HTML 50K 22: R4 Consolidated Statements of Operations and HTML 57K Comprehensive Loss 23: R5 Consolidated Statements of Stockholders' Equity HTML 89K 24: R6 Consolidated Statements of Stockholders' Equity HTML 25K (Parenthetical) 25: R7 Consolidated Statements of Cash Flows HTML 81K 26: R8 Organization and Description of the Business HTML 32K 27: R9 Summary of Significant Accounting Policies HTML 66K 28: R10 Fair Value Measurements HTML 65K 29: R11 Property and Equipment HTML 37K 30: R12 Accrued Expenses HTML 36K 31: R13 Leases HTML 43K 32: R14 Investments HTML 20K 33: R15 Stockholders' Equity HTML 146K 34: R16 Convertible Preferred Stock HTML 24K 35: R17 Commitments and Contingencies HTML 26K 36: R18 Income Taxes HTML 90K 37: R19 Summary of Significant Accounting Policies HTML 110K (Policies) 38: R20 Summary of Significant Accounting Policies HTML 50K (Tables) 39: R21 Fair Value Measurements (Tables) HTML 61K 40: R22 Property and Equipment (Tables) HTML 36K 41: R23 Accrued Expenses (Tables) HTML 35K 42: R24 Leases (Tables) HTML 37K 43: R25 Stockholders' Equity (Tables) HTML 142K 44: R26 Income Taxes (Tables) HTML 84K 45: R27 Organization and Description of the Business HTML 84K (Details) 46: R28 Summary of Significant Accounting Policies - HTML 31K Property and Equipment (Details) 47: R29 Summary of Significant Accounting Policies - Loss HTML 49K Per Share of Common Stock (Details) 48: R30 Summary of Significant Accounting Policies - HTML 20K Segment Information (Details) 49: R31 Fair Value Measurements (Details) HTML 33K 50: R32 Property and Equipment (Details) HTML 35K 51: R33 Accrued Expenses (Details) HTML 32K 52: R34 Leases (Details) HTML 67K 53: R35 Leases - Maturities (Details) HTML 43K 54: R36 Stockholders' Equity - Incentive Plans (Details) HTML 38K 55: R37 Stockholders' Equity - Stock Options and HTML 161K Restricted Stock (Details) 56: R38 Stockholders' Equity - Equity Distribution HTML 40K Agreement (Details) 57: R39 Stockholders' Equity - Public Offering (Details) HTML 38K 58: R40 Convertible Preferred Stock (Details) HTML 57K 59: R41 Commitments and Contingencies - Employee Benefit HTML 28K Plan and License Agreements (Details) 60: R42 Commitments and Contingencies - Employee and HTML 31K Severance Arrangements (Details) 61: R43 Income Taxes (Details) HTML 94K 63: XML IDEA XML File -- Filing Summary XML 103K 18: XML XBRL Instance -- mrns-20201231x10k_htm XML 1.40M 62: EXCEL IDEA Workbook of Financial Reports XLSX 73K 14: EX-101.CAL XBRL Calculations -- mrns-20201231_cal XML 138K 15: EX-101.DEF XBRL Definitions -- mrns-20201231_def XML 498K 16: EX-101.LAB XBRL Labels -- mrns-20201231_lab XML 1.11M 17: EX-101.PRE XBRL Presentations -- mrns-20201231_pre XML 789K 13: EX-101.SCH XBRL Schema -- mrns-20201231 XSD 124K 64: JSON XBRL Instance as JSON Data -- MetaLinks 280± 438K 65: ZIP XBRL Zipped Folder -- 0001558370-21-002646-xbrl Zip 406K
Exhibit 10.22
EMPLOYMENT AGREEMENT
EMPLOYMENT AGREEMENT effective as of June 15, 2020 between Marinus Pharmaceuticals, Inc. (the “Company”), a Delaware corporation, and Martha Manning (the “Employee”).
Recital:
The parties desire to enter into this Agreement so as to provide for the employment of the Employee by the Company and for certain other matters in connection with such employment, all as set forth more fully in this Agreement.
NOW, THEREFORE, in consideration of the premises and covenants set forth herein, and intending to be legally bound hereby, the parties to this Agreement hereby agree as follows:
Notwithstanding any provision of this Agreement to the contrary, in no event shall the timing of the Employee’s execution of the Release, directly or indirectly, result in the Employee designating the calendar year of payment, and if a payment that is subject to execution of the Release could be made in more than one taxable year, payment shall be made in the later taxable year.
shall be deemed excised from this Agreement, as the case may require, and this Agreement shall be construed and enforced to the maximum extent permitted by law as if such provision had been originally incorporated herein as so modified or restricted or as if such provision had not been originally incorporated herein, as the case may be.
If to the
Company:
Marinus Pharmaceuticals, Inc.
100 Matsonford Road
5 Radnor Corporate Center; Suite 500
Attention: Chief Executive Officer
If to the Employee, to address stated on the signature page to this Agreement.
Any party may from time to time change its address for the purpose of notices to that party by a similar notice specifying a new address, but no such change shall be deemed to have been given until it is actually received by the party sought to be charged with its contents.
interpretations (together, “Section 409A”) issued pursuant to Section 409A so as not to subject the Employee to payment of interest or any additional tax under Code section 409A. The parties intend for any payments under this Agreement to either satisfy the requirements of Section 409A or to be exempt from the application of Section 409A, and this Agreement shall be construed and interpreted accordingly. In furtherance thereof, if payment or provision of any amount or benefit hereunder that is subject to Section 409A at the time specified herein would subject such amount or benefit to any additional tax under Section 409A, the payment or provision of such amount or benefit shall be postponed to the earliest commencement date on which the payment or provision of such amount or benefit could be made without incurring such additional tax. In addition, to the extent that any Internal Revenue Service guidance issued under Section 409A would result in the Employee being subject to the payment of interest or any additional tax under Section 409A, the parties agree, to the extent reasonably possible, to amend this Agreement in order to avoid the imposition of any such interest or additional tax under Section 409A, which amendment shall have the minimum economic effect necessary and be reasonably determined in good faith by the Company and the Employee.
(Signature page follows.)
IN WITNESS WHEREOF, this Agreement has been executed by the parties.
MARINUS PHARMACEUTICALS, INC.
By: /s/ Scott
Braunstein, MD May 22, 2020
Scott Braunstein, MD Date
Chief Executive Officer
/s/ Martha Manning, Esq. May 22, 2020
Martha Manning, Esq Date
Schedule A
Activities not subject to Section Section 5(b)
Non-Competition
1)Continuing activities with pre-existing contracted consulting/employment commitments (entered into prior to the effective date of this Agreement) and/or minimal ownership interests (five percent (5%) or less) in the following companies and/or their current or future subsidiaries:
None
This ‘10-K’ Filing | Date | Other Filings | ||
---|---|---|---|---|
Filed on: | 3/9/21 | 4, 8-K | ||
For Period end: | 12/31/20 | |||
6/15/20 | 3, 4, 8-K | |||
5/22/20 | ||||
List all Filings |
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 3/05/24 Marinus Pharmaceuticals, Inc. 10-K 12/31/23 79:10M Toppan Merrill Bridge/FA 3/09/23 Marinus Pharmaceuticals, Inc. 10-K 12/31/22 73:10M Toppan Merrill Bridge/FA 3/24/22 Marinus Pharmaceuticals, Inc. 10-K 12/31/21 71:8.5M Toppan Merrill Bridge/FA 8/10/21 Marinus Pharmaceuticals, Inc. S-8 8/10/21 5:200K Toppan Merrill/FA |